Skip to main content
. 2023 Mar 24;37(2):152–163. doi: 10.1177/19714009231166090

Figure 4.

Figure 4.

Subgroup analysis based on medicine type used for remission outcome. Abciximab: 12 studies with an average remission rate of 92% and p < .001; I2 = 66.28. Tirofiban: Four studies with an average remission rate of 86% and p < .00; I2 = 77.48. Tirofiban and abciximab: One study with an average remission rate of 97% and p: NA. Eptifibatide: Two studies with an average remission rate of 82% and p < .001; I2 = 0.